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Abstract
Background: The majority of patients with hilar cholangiocarcinoma have irresectable disease and
require palliation with biliary stenting to alleviate symptoms and prevent biliary sepsis. Chemotherapy and
radiotherapy have proved ineffective, but recent studies suggest photodynamic therapy (PDT) may
improve the outlook for these patients. This prospective clinical cohort study has evaluated the efficacy
of radical curative surgery, standard palliative therapy (stent  chemotherapy) and a novel palliative
therapy (stent  Photofrin-PDT) in 50 consecutive patients treated for hilar cholangiocarcinoma over a
5-year period.hpb_102 570..577
Methods: Between January 2002 and December 2006, 50 patients with hilar cholangiocarcinoma were
evaluated for treatment. Ten patients were considered suitable for curative resection (Cohort 1). Forty
patients with irresectable disease were stratified into Cohort 2 – Stent  chemotherapy (n = 17); and
Cohort 3 – Stent  PDT (n = 23). Prospective follow-up in all patients and data collected for morbidity,
mortality and overall patient survival.
Results: The median age was 68 years [range 44–83]. Positive cytology/histology was obtained in 28/50
(56%). One death in Cohort 1 occurred at 145 days after surgical resection. No treatment related-deaths
occurred in Cohort 2 or 3, chemotherapy-induced morbidity in three patients in cohort 2, PDT-induced
morbidity in 11 patients in cohort 3. Actual 1-year survival was 80%, 12% and 75% in Cohorts 1, 2 and
3, respectively. Mean survival after resection was 1278 days (median survival not reached). Mean and
median survival was 173 and 169 days, respectively, in Cohort 2; and 512 and 425 days in Cohort 3.
Patient survival was significantly longer in cohorts 1 and 3 (P < 0.0001; Log rank test).
Conclusion: This prospective clinical cohort study has demonstrated that radical surgery and palliative
Photofrin-PDT are associated with an increased survival in patients with hilar cholangiocarcinoma.
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Introduction
Hilar cholangiocarcinoma was first described by Altemeir et al. in
1957,1 but it was only after Klatskin described a series of 13 patients
in 1965 that this tumourwas recognized as a distinct clinical entity.2
These uncommon tumours have an incidence of 1.2 per 100,000 in
the western population3,4 and account for 60–70% of all primary
bile duct cancers.4–6 Hilar cholangiocarcinoma has an extremely
poor prognosis with less than 5% of patients surviving 5 years.7
Surgical resection offers the only curative option and usually
requires a major hepatic resection in addition to resection of the
actual bile duct cancer.8 Unfortunately, curative resection is only
possible in 20% of patients because of locally advanced disease,
distant metastases or co-morbidity in an elderly population.9
Therefore, effective palliation to relieve the symptoms
associated with jaundice and the prevention of biliary tract
infection are the fundamental goals for most patients with hilar
cholangiocarcinoma. Relief of biliary tract obstruction by
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endoscopic or percutaneous placement of plastic or metal stents is
regarded the optimal first-line palliation as this achieves similar
survival (6.8 months vs. 5.4 months) to surgical bypass, but with
less procedure-related morbidity (17–51%) or mortality (6–12%)
and at substantially lower cost.8–11
However, even after successful stent insertion the clinical course
is one of disease progression and death from liver failure or cho-
langitis within 4–9months.7,12–14 Many studies have evaluated che-
motherapy, external beam radiotherapy and brachytherapy but
have not demonstrated a meaningful survival benefit in this
patient population.15–18
As a result, novel therapies such as photodynamic therapy
(PDT) are being evaluated for treatment of cancers that have
proved resistant to standard oncological treatment. PDT destroys
cancerous tissue by stimulating a photochemical reaction within
the lesion using the combination of a photosensitizing drug and
a specific wavelength of light.19 The photosensitizer drug is acti-
vated by intense illumination with (laser) light to generate highly
reactive oxygen species that result in cellular injury. This photo-
dynamic reaction destroys cancerous tissue by direct cytotoxicity,
microvascular damage,20 cytosolic and mitochondrial membrane
damage; and release of inflammatory mediators that induce a
T-lymphocyte-mediated cellular immune response.21–23
Preliminary clinical studies have suggested that PDT may be
beneficial for palliation of hilar cholangiocarcinoma24–28 and a
recent study demonstrated a substantial survival benefit for PDT
in jaundiced patients with advanced cholangiocarcinoma.29 The
aim of this prospective clinical cohort study was to evaluate the
efficacy of radical curative surgery, standard palliative therapy
(stent  chemotherapy) and a novel palliative therapy (stent 
Photofrin-PDT) in the management of patients with hilar
cholangiocarcinoma.
Patients and methods
Patients
Fifty-four patients with hilar cholangiocarcinoma were assessed at
the Hepatobiliary unit at Ninewells Hospital & Medical School
between January 2002 and December 2006, and 50 patients suit-
able for active treatment were included in the study. This single
centre study included 10 patients referred for PDT from other
Scottish hospitals. Patients aged at least 18 years with a hilar cho-
langiocarcinoma (Bismuth types II–IV) were considered for
inclusion in the study, and the use of Photofrin-PDT for bile duct
cancer was approved by the Tayside Regional Ethics committee.
Four frail patients with extensive metastatic disease were consid-
ered too unfit for any palliative treatment and were, therefore,
excluded from further study.
Definition of hilar lesion
Hilar strictures were graded according to Bismuth.30 Type I lesions
involved the proximal hepatic duct while sparing the confluence;
type II lesions involved the bifurcation but did not extend into the
right of left segmental hepatic ducts; type III A and B lesions
involved the confluence and extended into the segmental right
and left hepatic ducts respectively; and type IV lesions involved
the confluence and extended into both left and right segmental
hepatic ducts. Confirmatory histology or cytology was desirable,
but the absence of positive cytology did not exclude patients from
undergoing treatment in the presence of unequivocal radiological
evidence. All patients were reviewed by a specialist HPB radiolo-
gist, HPB surgeon and HPB oncologist at the multi-disciplinary
meeting (MDT) to confirm the diagnosis of hilar cholangiocarci-
noma in the absence of positive cytology.
Evaluation for treatment
All patients presented with clinical jaundice or deranged liver
function that was first evaluated by abdominal ultrasonography,
followed by a multi-slice CT scan of the chest, abdomen and
pelvis. Patients that were considered for curative surgery were
further evaluated by contrast enhanced magnetic resonance
imaging (MRI) followed by staging laparoscopy. Loco-regional
tumour irresectability was defined according to the criteria
proposed by Chamberlain and Blumgart: Bismuth IV tumours;
encasement or occlusion of the main portal vein; lobar atrophy
with contralateral portal vein involvement; evidence of metastasis
to N2 level lymph nodes; and presence of distant metastases.31
Clinical cohorts
All patients within the 5-year study period were prospectively
monitored until death (or study end-point – December 2006).
Patients with intra-hepatic cholangiocarcinoma (IHCC) were not
eligible, whereas patients with a mass-forming hilar cholangiocar-
cinoma were included in the study. All lesions were stratified
according to Bismuth Classification (Table 1) irrespective of the
size of the mass lesion at the hilum.
Table 1 Patient demographics: Bismuth classification – tumour
extent. Cohort 1: surgical resection; Cohort 2: stent  chemo-
therapy; Cohort 3: stent  PDT
Cohort 1
(n = 10)
Cohort 2
(n = 17)
Cohort 3
(n = 23)
Age (year) (range) 69 (25–78) 65 (44–82) 69 (56–83)
Gender (male/female) 3/7 7/10 13/10
Karnofsky status (%) 90 (65–100) 70 (30–95) 75 (30–100)
Tumour extent(14)
Type I – – –
Type II 2 1 1
Type IIIa 5 4 8
Type IIIb 3 1 2
Type IV – 11 12
Positive histology 3 9 16
Liver metastases (Stage
IV disease)
0 2 3
PDT, photodynamic therapy.
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Patients were reviewed in the hepatobiliary oncology MDT
meeting to determine suitability for radical surgery or palliative
therapy. Only patients with a life expectancy > 6 weeks were con-
sidered for systemic chemotherapy or photodynamic therapy
(PDT). Four patients with extensive liver metastases (>40% liver
volume replaced with tumour) and severe cardiac co-morbidity
were considered ineligible for any further treatment and were
offered symptom support only.
All eligible patients (n = 40) undergoing palliative treatment
were offered the choice of (i) standard therapy of stenting 
chemotherapy as directed by the multi-disciplinary team or (ii)
stent  PDT.
Patients choosing standard therapy were informed that chemo-
therapy may in some cases prevent disease progression for a
limited period. Patients choosing PDT were informed that PDT
was an experimental treatment that caused local tumour destruc-
tion that may improve liver function and survival, but also caused
severe skin photosensitivity for up to 8 weeks which would tem-
porarily compromise quality of life.
Contra-indications to PDT were (i) age <18, (ii) history of
porphyria or skin photosensitivity, (iii) life expectancy less than 6
weeks, (iv) and extensive metastatic liver disease (>40%). Four
frail elderly patients were excluded on the basis of extensive meta-
static liver disease and a predicted survival of less than 6 weeks.
After appropriate out-patient counselling, 17/40 patients
selected standard palliative therapy (stent  chemotherapy), and
23/40 patients selected stent  PDT.
Cohort 1
Cohort 1 comprised of patients with resectable disease that pro-
ceeded to radical surgery which included a hepatic resection and
caudate lobectomy as standard procedure. Patients with Type IIIa
lesions (n = 5) underwent pre-operative portal vein embolization
4–6 weeks prior to extended right hepatectomy (S4-8 plus S1).
Cohort 2
Cohort 2 comprised of 17/40 patients with irresectable disease
that selected standard therapy as primary palliation. Of these 17
patients, 8 received systemic chemotherapy (n = 8). Chemo-
therapy was not given to nine patients as a result of persistent
jaundice despite biliary tree stenting (bilirubin > 50 mmol/l),
clinical deterioration or patient decision. The decision to com-
mence, withhold or stop chemotherapy was undertaken by the
medical oncologist.
Cohort 3
Cohort 3 comprised of 23/40 patients with irresectable disease
that selected biliary stent  PDT as primary palliation. All 23
patients underwent PDT as jaundice is not a contra-indication to
treatment.
Follow-up for all patients included a clinical out-patient review
at 6 and 12 weeks after definitive first treatment, and 3-monthly
clinical out-patient review thereafter. Cross-sectional imaging was
repeated at 3, 6 and 12 months, and serial liver function tests
[serum bilirubin, alanine aminotransferase (ALT), albumin, alka-
line phosphatase (AP), Gamma-glutamyltranspeptidase (gamma-
GT)], and the tumour marker CA19.9 were collected at each
follow-up visit.
The primary end-point of the study was patient survival. Sec-
ondary end-points were PDT toxicity and other treatment related
side effects. All data were collected prospectively.
Biliary tree decompression at presentation
During their index admission, all patients had a biliary tree stent
inserted to relieve jaundice (if possible) and associated symptoms,
and multiple brushings obtained for cytology.32 Patients that
presented initially to the Ninewells Hospital hepatobiliary unit
underwent biliary tree decompression with insertion of a plastic
stent. Seven patients referred from other Institutions had a self-
expandable metal stent (SEMS) inserted prior to referral, and
these patients had palliative PDT from within the lumen of the
SEMS. PDT has been shown to have similar efficacy when deliv-
ered from within a metal stent.29
Curative surgery
Patients with resectable disease underwent partial hepatectomy
and caudate lobectomy together with resection of the primary bile
duct cancer as standard procedure. Patients with Bismuth Type
IIIa lesions required extended hepatic resection and therefore had
right portal vein and segment 4 venous embolization (PVE) 4–6
weeks prior to surgery. A CT scan was performed at 4 weeks to
confirm future remnant liver (segment 2–3) hypertrophy prior to
proceeding with definitive surgery.
Chemotherapy
Chemotherapy was directed by a specialist hepatobiliary medical
oncologist and patients were treated with ECF (Epirubicin 50 mg/
m2, Cisplatin 60 mg/m2, Fluorouracil 600 mg/m2) or Gemcitabine
1 g/m2. Chemotherapy was stopped when there was (i) radiologi-
cal evidence of disease progression or (ii) severe clinical side
effects. Biliary tree re-intervention was carried out ‘on-demand’ if
patients presented with cholangitis or jaundice during follow-up.
There was no routine planned prophylactic stent change in any
patient.
Photodynamic therapy
Photofrin® (Axan Pharma Inc., Mount-Saint-Hilaire, Canada)
was administered by slow intravenous injection over 5 min at a
dosage of 2 mg/kg 48 h before laser activation. All patients
received prophylactic antibiotic cover with ciprofloxacin 500 mg,
and this was continued twice daily for 2 weeks after PDT. PDT was
performed in the radiology suite to provide fluoroscopy imaging
and the procedure was carried out under intravenous sedation
(midazolam 6–16 mg, pethidine 25–50 mg, Hyoscine Butylbro-
mide 20–80 mg) with cardiac and respiratorymonitoring.Oxygen
was delivered via a nasal cannula to optimize the effect of the PDT.
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Access to the biliary tree was obtained via an ERC duodenos-
cope or a percutaneous transhepatic catheter (PTC). The optical
diffuser fibres delivered 200 mW/cm with an active tip length of
40 mm (CD 405-40 C, BioLitec AG, Jena, Germany). The optical
fibre was coupled to a Diomed 630 laser (Diomed, Cambridge,
UK) delivering light at a wavelength of 630 nm, which is the
optimum wavelength for activation of Photofrin®. The total light
dose delivered to the tumour was 180 J/cm. After PDT, the proce-
dure was concluded by immediate insertion of a biliary stent. A
single 10F plastic or 10 mm metal stent was placed across the
tumour into the left or right side of liver – to preferentially drain
the biliary system with most preserved functional liver volume.32
We consider it important that PDT is tailored towards the liver
segments with most functional reserve and this may be delivered
via ERC or PTC. Care is taken to avoid contrast injection into
un-drained segments, and both stent placement and the PDT
procedure are best planned using pre-treatment magnetic reso-
nance cholangiopancreatography (MRCP).
Patients received one PDT treatment only in the study period,
and biliary tree re-intervention was carried out ‘on-demand’ if
patients presented with jaundice or cholangitis in the follow-up
period. There was no routine planned prophylactic stent change in
any patient.
Statistical Analysis
SPSS® version 16.0 was used for statistical analysis (SPSS Inc.,
Chicago, IL, USA). Patient survival is presented as mean and
median [95% confidence intervals (95% CI)] value for each
cohort. Patient survival curves were calculated using Kaplan–
Meier methodology and differences in survival between cohorts
were tested using the log-rank test. A P-value <0.05 was consid-
ered to be statistically significant.
Results
Patient cohorts
During the study period, 54 patients were referred to the Unit with
a diagnosis of hilar cholangiocarcinoma (Table 1). Four patients
with severe co-morbidity and extensive metastatic disease (>40%)
were not fit for any type of treatment and therefore excluded from
any further analysis. The 50 patients suitable for active treatment
are the subject of this prospective clinical cohort study.
Ten patients (10/50) had resectable disease and proceeded to
undergo radical surgery (Cohort 1). The remaining 40 patients
were considered unsuitable for radical resectional surgery and
were considered for palliative therapy only. Of these 40 patients,
four had resectable disease (Bismuth Type IIIa) but were consid-
ered unsuitable for extended hepatic resection as a result of severe
co-morbidities (ischaemic heart disease and diabetes mellitus in
all four). One of these four patients selected standard palliative
therapy, and three selected palliative PDT. Ten out of the 40
patients with irresectable disease were referred from other hepa-
tobiliary centres in Scotland, and 7 of these 10 patients had a
SEMS in situ.
Cohort 1: curative resection
Ten patients underwent laparotomy and trial dissection and all
proceeded to curative resection. Pre-operative biliary drainage
was performed routinely, and the future remnant liver was
drained in patients undergoing PVE prior to surgery. Five patients
required pre-operative PVE prior to extended right hepatectomy
plus caudate lobectomy.
One patient developed progressive and irreversible hepatic dys-
function in the post-operative period after extended right hepa-
tectomy and died from multi-organ failure 145 days after liver
resection. A second patient required a re-look laparotomy at 5
weeks for a persistent bile leak from a peripheral duct that was
oversewn. The median hospital stay after liver resection was 14
days (range 8–145 days).
Positive pre-operative cytology was obtained in 3 out of 10
patients, but histology of the resected specimen confirmed hilar
ductal adenocarcinoma in all 10 patients. An R0 curative resection
with negative resection margins was achieved in all cases but
positive regional lymph node metastases were noted in four cases.
Cohort 2: standard palliative therapy
Seventeen out of 40 patients with irresectable disease selected
biliary stent  systemic chemotherapy (in preference to PDT) as
their primary palliation. Eight of these 17 patients actually
received systemic chemotherapy under the direction of a hepato-
biliary medical oncologist. These patients received 2 to 12 cycles of
chemotherapy with a mean of 4 cycles per patient. One patient
demonstrated a radiological response after 3 cycles, 5 patients had
stable disease after 3 cycles, and 2 patients demonstrated progres-
sive disease after 3 cycles and chemotherapy was withdrawn.
Three out of five patients with stable disease stopped chemo-
therapy after the fourth cycle because of treatment side effects
and/or disease progression. The remaining nine patients did not
commence chemotherapy as a result of a deterioration in clinical
condition (n = 4), persistent jaundice (n = 3) or patient decision
(n = 2).
Cohort 3: biliary stent + Photofrin PDT
Twenty-three out of 40 patients with irresectable disease selected
biliary stent  photodynamic therapy as their palliative treat-
ment. PDT was delivered as a single treatment, and was delivered
at a median of 2.5 months (range 1.5–7 months) after diagnosis.
Access to the biliary tree for delivery of PDTwas by duodenoscope
(ERC) in 19 patients and percutaneous fluoroscopy (PTC) in 4
patients. All patients that received the photosensitiser drug sub-
sequently underwent successful PDT at 48 h. All patients were
treated as hospital in-patients (from day 1 – drug injection), and
received intravenous saline for 48 h after PDT. The median hos-
pital stay for PDT was 9.8 days (range 4–32 days), with the obser-
vation that patients referred from other Scottish centres stayed
2–4 days longer than local patients.
Jaundice resolved in 21 out of 23 patients after PDT,with biliru-
bin levels dropping to below 40 mmol/l at 4 weeks after PDT.
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Positive histology or cytology was obtained in 16 out of 23
patients, and 5 further patients demonstrated disease progression
with metastatic disease on serial follow-up imaging. One patient
with a Bismuth Type IIIb lesion met all clinical and radiological
criteria in the absence of positive cytology, and remains clinically
well with no evidence of metastatic disease at 36 months after
PDT.
PDT was reasonably well tolerated, with 10 out of 23 patients
reporting mild abdominal pain or discomfort for 2–3 days after
PDT. This was treated by simple analgesia and close clinical obser-
vation and resolved in all cases.
Early side-effects (7 days) were observed in 7 out of 23 PDT
patients. Five patients became unwell with clinical signs of septi-
caemia in the first 24 h after PDT, and required intravenous fluid
replacement and antibiotic therapy. These patients recovered
within 48 h and were tolerating normal oral fluids and diet by 72 h
after PDT.
Two further patients had a significant haematemesis with car-
diovascular compromise within 24 h of PDT. Both patients dem-
onstrated a significant haemoglobin drop to less than 8 gm/dl and
required a three-unit blood transfusion of red cell concentrate.
Upper GI endoscopy was normal in both patients and it is postu-
lated that these two patients had haemobilia secondary to the
biliary tree instrumentation, balloon dilatation and PDT of the
hilar lesion. The bleeding was thought to be secondary to direct
instrumentation-related trauma, rather than tumour invasion of
the portal vessels at the hilum.
Late side-effects (>7 days) were noted in 4 out of 23 patients.
Despite extensive counselling by staff about the risk of Photofrin®
photosensitivity, four patients inadvertently exposed themselves
to direct sunlight and developed minor skin irritation as a conse-
quence. However, this amounted to minor inflammation that was
alleviated by anti-histamine emollient cream (Table 2).
After PDT, most patients were re-admitted to their local hospi-
tal or the study centre hospital on at least one occasion (mean
1.69; median 1: range 0–6). The reasons for re-admission were
cholangitis, progression of jaundice or derangement of liver
function, and/or suspected stent occlusion. After re-admission,
patients underwent further cross-sectional imaging to document
disease progression, clarify symptom aetiology and plan a strategy
for further biliary tract intervention.
Survival
At the predetermined end-point (31 December 2006) of this
observational study, 4/10 patients in cohort 1, 16/17 patients in
cohort 2 and 18/23 patients in cohort 3 had died of progressive
disease. The median follow-up for the 40 patients was 25.1
months (range 3–46 months).
The 1-year survival rate was 80% in cohort 1, 12% in cohort 2
and 75% in cohort 3. In cohort 1, the mean (95% CI) survival was
1278 (632, 1923) days and the median survival has not yet been
reached. In cohort 2, the mean (95% CI) and median (95% CI)
survival was 173 (120, 226) days and 169 (120, 217) days, respec-
tively, which is similar to survivals reported by others for Bismuth
Type III-IV hilar cholangiocarcinoma (3–13).
The mean (95% CI) and median (95% CI) survival in cohort 3
was 512 (366, 658) and 425 (260, 589) days, respectively. The
median survival observed in cohort 3 is substantially longer than
that observed in cohort 2, and this difference in survival is highly
significant (log rank P < 0.0001).
The Kaplan–Meier survival curves for each patient cohort are
illustrated in Fig. 1, and the survival curves for each cohort are
Table 2 PDT-related adverse events
Stent + PDT
n = 23
Abdominal pain 10
Early side effects (<7 days) 7
Biliary sepsisa 5
Haematemesisa 2
Late side effects (>7 days) 4
Skin Photosensitivityb 4
PDT, photodynamic therapy.
aProbably related to procedure related instrumentation.
bRelated to Photofrin® administration.
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Figure 1 Overall survival – hilar cholangiocarcinoma. Cohort 1: cura-
tive surgery; Cohort 2: stent  chemotherapy; Cohort 3: stent 
photodynamic therapy (PDT). Cohort 1 – mean [95% confidence
interval (CI)] survival 1278 (632, 1923) days, median survival not
reached. Cohort 2 – mean (95% CI) survival 173 (120, 226) days and
median (95 CI) survival 169 (120, 217) days. Cohort 3 – mean (95 CI)
survival 512 (366, 658) days and median (95 CI) survival 425 (260,
589) days
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truncated when the number at risk are less than 30% of the initial
cohort size.
Discussion
Hilar cholangiocarcinoma is the most common primary cancer of
the biliary tract in the United Kingdom with approximately 650
new cases per annum.Whilst curative resection is possible in 20%,
most patients require effective palliation. The median predicted
survival in those with irresectable disease is approximately 4–6
months.11–14,34,35 Hilar bile duct cancers spread along the biliary
tree to cause progressive bile duct obstruction, hepatic dysfunc-
tion and potentially fatal biliary sepsis. Therefore a targeted
therapy that is able to control cancer growth at a local level has the
theoretical benefit that it may improve drainage of the extra- and
intra-hepatic biliary tree, maintain hepatic function and second-
arily reduce the risk of serious (potentially fatal) biliary tract
infection.
PDT is a non-thermal palliative therapy that causes localized
and targeted tissue destruction, induces a systemic T-cell medi-
ated immune response and can be delivered to remote body sites
via flexible optical fibres. Therefore PDT has characteristics that
are well suited for the palliation of hilar bile duct cancer, and may
provide a clinical benefit to patients that have an otherwise
extremely bleak outlook.
Several studies report PDT as an effective palliative option, but
this modality is not widely available and is not yet considered a
standard therapy for patients with hilar bile duct cancer in the
United Kingdom. Therefore, this prospective clinical cohort study
has compared the current standard palliative therapy of bile duct
stent  chemotherapy with the novel combination of bile duct
stent PDT for palliation of patients with irresectable hilar cho-
langiocarcinoma. All patients were followed up prospectively to
provide insight into the impact that these palliative treatment
modalities have on this disease. In this study, it was our experience
that PDT is associated with an increased survival in patients with
irresectable disease.
Previous studies have established that after surgical biliary
bypass (drainage) or biliary stenting the median survival is
approximately 4–10 months.7,33,35,36–39 In the present study, the
median survival observed with standard treatments (i.e. cohort 2)
was 6 months, which is similar to that predicted and reported in
other studies.7,33,35,36–39 To date, trials with systemic chemotherapy
have demonstrated radiological responses of 20–40%,40–42 but
limited clinical efficacy in terms of survival gains.43,44
In contrast, several phase II studies25,27,28,45 and a randomized
controlled trial29 have demonstrated a significant survival advan-
tage with PDT, with median survivals ranging from 330–493 days
after diagnosis and a 1-year survival of 45–75%.25,26 In this study,
the actual 1-year survival after PDT (cohort 3) was 75%, and the
median survival was 425 days. This survival is similar to that
reported by Ortner et al.,29 and substantially longer than that nor-
mally predicted for this patient population,7,33,35,36–39 and signifi-
cantly longer than that observed with standard palliative
treatment (stent  chemotherapy) (P = 0.0001 Log rank test).
When one considers the palliative options available for patients
with hilar cholangiocarcinoma, PDT offers a single minimally
invasive treatment that has a low complication rate, and is well
tolerated by patients. In our experience, the side effects of PDT
were predictable and relatively easy to treat. When using Photof-
rin® for biliary PDT, phototoxicity is an inevitable side effect that
lasts for 6 to 8 weeks after drug administration. However, patients
regarded the avoidance of direct sunlight and intense light as a
minor inconvenience.
It was observed that segmental drainage and biliary tract
decompression was successful in 21 out of 23 patients undergoing
PDT with a 50% reduction in serum bilirubin at 1 month after
PDT. An advantage of PDT in hilar cholangiocarcinoma is that it
may be delivered to jaundiced patients (unlike chemotherapy) to
cause targeted destruction of the intra-luminal tumour at the
biliary confluence. This may improve segmental liver drainage
and this is supported by recent studies that report a reduction in
cholestasis with bile duct PDT.25–29,46
Difficulties in obtaining histopathological confirmation of the
diagnosis in patients with hilar cholangiocarcinoma are well rec-
ognized. This is related to the difficulty in acquisition of adequate
cytology and histology,47 with sensitivities of <50% and <63%
reported as either single or combined diagnostic modalities,
respectively.48 We recognize that in this study positive cytology
could not be obtained in all patients prior to treatment. However,
this reflects this recognized difficulty with hilar cholangiocarci-
noma, and all patients within this study had multiple biliary
brushings for cytology and confirmed malignancy in 16 out of 23
patients undergoing PDT. Five further PDT patients demon-
strated unequivocal evidence of cancer progression on serial
cross-sectional imaging, and 18/23 PDT patients have died of
cancer progression during the study follow-up period. To date,
new techniques such as in situ hybridization and fluorescence
in situ hybridization (FISH) analysis have been unable to improve
the diagnostic accuracy beyond that obtained using biliary brush-
ings and cytology.49,50
Modern surgical strategies for hilar cholangiocarcinoma
require the resection of substantial volumes of functional liver
parenchyma to ensure clear resection margins which clearly
increases the surgical risk and in-hospital mortality
(0–18%).34,36–38,51–55 However, this radical approach to curative
resection can achieve 5-year survival rates of 20–40%, especially
in the absence of regional lymph node metastases.34,36,37,51,53–56
Witzigmann et al. recently reported their experience of 156
patients with hilar chilangiocarcinoma and demonstrated that
an R0 curative resection remains the optimal treatment.
However, in their experience patients with irresectable disease
treated with PDT had a survival similar to that of patients that
underwent an incomplete R1 or R2 surgical resection56 and this
observation further supports PDT as a beneficial palliative
therapy in hilar cholangiocarcinoma.
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Historically the prognosis for patients with irresectable hilar
cholangiocarcinoma has been poor. However, this single centre
prospective clinical cohort study has demonstrated that radical
surgery offers the possibility of cure for a small proportion of
patients, and also that palliative PDT is associated with an
improvement in patient survival. While the outcomes associated
with PDT for irresectable hilar cholangiocarcinoma in this phase
2 clinical observational study are encouraging, we await with
interest the survival data from the Photostent-02 multi-centre
randomized controlled trial that is due to report in 2012.
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